Identification of new sensitive biomarkers for the in vivo response to interferon-β treatment in multiple sclerosis using DNA-array evaluation

European Journal of Neurology

Volumn 16, Issue 12, 2009, Pages 1291-1298

  Sellebjerg, F ^a   Krakauer, M ^a   Hesse, D ^a   Ryder, L P ^a   Alsing, I ^a   Jensen, P E H ^a   Koch Henriksen, N ^b   Svejgaard, A ^a   Soelberg Sorensen P ^a  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarkers; Gene expression; Interferon ; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; COMPLEMENTARY DNA; DNA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON ALPHA INDUCED PROTEIN 27; MONOCYTE CHEMOTACTIC PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; RNA; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINE CXCL10; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MEMBRANE PROTEINS; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70450162691     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02716.x     Document Type: Article

References (35)

1. Marrie RA, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006 2 : 34 44.
2. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 2007 14 : 850 859.
3. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 12 : 817 827.
4. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007 68 : 977 984. (Pubitemid 46569129)
5. Sorensen PS, Koch-Henriksen N, Bendtzen K. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007 13 : 616 621.
6. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005 65 : 33 39.
7. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006 12 : 247 252.
8. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999 52 : 1277 1279.
9. Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003 215 : 3 8.
10. Gneiss C, Reindl M, Lutterotti A, et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004 10 : 507 510.
11. Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Mult Scler 2008 14 : 837 842.
12. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001 21 : 743 755.
13. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001 21 : 729 742.
14. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998 50 : 1266 1272.
15. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999 52 : 1239 1243.
16. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006 67 : 1681 1683.
17. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001 256 : 141 152.
18. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003 60 : 634 639.
19. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003 7 : 17 25.
20. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005 166 : 180 188.
21. Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 2006 176 : 125 133.
22. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008 79 : 57 62.
23. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006 12 : 47 57.
24. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 2006 66 : 444 446.
25. Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008 14 : 615 621.
26. Ross C, Clemmesen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006 12 : 39 46.
27. Benjamini Y, Hoffmann F. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodol) 1995 57 : 289 300.
28. Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003 171 : 2694 2702.
29. Reder AT, Velichko S, Yamaguchi KD, et al. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008 28 : 317 331.
30. Gilli F, Marnetto F, Caldano M, et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005 158 : 195 203.
31. Rasmussen UB, Wolf C, Mattei MG, et al. Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res 1993 53 : 4096 4101.
32. Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest 2007 117 : 3107 3117.
33. Buttmann M, Merzyn C, Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004 156 : 195 203.
34. Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 2006 64 : 155 163.
35. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008 70 : 1119 1127.